Stockholders’ Deficit (Tables)
|
3 Months Ended |
Apr. 30, 2026 |
| Equity [Abstract] |
|
| Schedule of Reserved Shares of Common Stock |
The Company has reserved shares of its common stock for future issuance as follows (in thousands): | | | | | | | | | | | | | | | | | April 30, | | January 31, | | | 2026 | | 2026 | | | | | | | | | | | 2014 Stock Option and Grant Plan: | | | | | | Outstanding stock options | | 8,818 | | | 8,970 | | | Outstanding restricted stock units | | 6,200 | | | 9,227 | | | | | | | 2024 Equity Incentive Plan: | | | | | | Outstanding restricted stock units | | 16,898 | | | 12,294 | | | Shares available for future issuance under the 2024 Plan | | 64,061 | | | 58,406 | | | 2024 Employee Stock Purchase Plan | | 6,571 | | | 5,090 | | | Total shares of common stock reserved | | 102,548 | | | 93,987 | |
|
| Schedule of Stock Options Roll Forward |
A summary of the stock option activity and related information is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Number of Options | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Term (years) | | Aggregate Intrinsic Value (in thousands) | | Outstanding as of January 31, 2026 | 8,970,353 | | | $ | 29.20 | | | 7.6 | | $ | 239,954 | | | Granted | — | | | — | | | — | | | — | | | Exercised | (152,660) | | | 4.21 | | | — | | | 7,200 | | | Cancelled | — | | | — | | | — | | | — | | | Outstanding as of April 30, 2026 | 8,817,693 | | | $ | 29.63 | | | 7.4 | | $ | 207,630 | | | Vested and exercisable as of April 30, 2026 | 3,649,981 | | | $ | 26.28 | | | 6.7 | | $ | 98,168 | |
|
| Schedule of Nonvested Restricted Stock Units Activity |
A summary of the RSU activity and related information is as follows: | | | | | | | | | | | | | Number of RSUs | | Weighted-Average Grant Date Fair Value | | Unvested as of January 31, 2026 | 21,480,571 | | | $ | 48.73 | | | Granted | 6,648,891 | | | 49.04 | | | Vested | (2,840,496) | | | 35.17 | | | Forfeited | (2,191,311) | | | 43.37 | | | | | | | | | | | Outstanding as of April 30, 2026 | 23,097,655 | | | $ | 51.00 | |
|
| Schedule of the Assumptions Used in Estimating Fair Value of ESPP |
The Company estimated the fair value of ESPP purchase rights using a Black-Scholes option-pricing model with the following assumptions: | | | | | | | | | | | | | | | | | | | Three Months Ended April 30, | | | | | | 2026 | | 2025 | | Expected term (in years) | | | | | 0.5 - 2.0 | | 0.5 - 2.0 | | Expected volatility | | | | | 59.4% - 61.2% | | 59.0% - 64.7% | | Risk-free interest rate | | | | | 3.8% - 3.8% | | 3.9% - 4.3% | | Dividend yield | | | | | — | | — |
|
| Schedule of Stock-Based Compensation Expense |
Total stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations was as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | Three Months Ended April 30, | | | | | | | 2026 | | 2025 | | Cost of revenue | | | | | | | | | | Subscription | | | | | | $ | 4,631 | | | $ | 3,968 | | | Other | | | | | | 634 | | | 857 | | | Research and development | | | | | | 33,026 | | | 19,812 | | | Sales and marketing | | | | | | 16,331 | | | 24,144 | | | General and administrative | | | | | | 18,746 | | | 24,759 | | | Total stock-based compensation expense | | | | | | $ | 73,368 | | | $ | 73,540 | |
|